Skip to main content
Premium Trial:

Request an Annual Quote

VTT of Finland Licenses GeneGo's Software for Cancer Studies

NEW YORK (GenomeWeb News) – GeneGo said today that the VTT Technical Research Centre of Finland, a developer of novel high-throughput methods for cancer research, drug discovery, and diagnostics, has licensed the company’s software suite.
 
Under the agreement, VTT will use the MetaCore and MetaDrug software in compound screening, RNA interference experiments, cell biology, and bioinformatics projects to identify pathways and networks for cancer research projects.
 
These projects include studies of the mechanisms of cancer development and progression, therapeutics research, and the actions of anti-cancer compounds.
 
VTT’s Medical Biotechnology Knowledge Centre is funded by the European Commission and the Academy of Finland.
 
Financial terms of the agreement were not released.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.